Literature DB >> 7893989

Bone marrow hypoplasia and fibrosis following interferon treatment.

A Hoffmann1, E Kirn, G R Krueger, R Fischer.   

Abstract

Interferon treatment is known to cause hematologic changes such as thrombocytopenia, anemia and granulocytopenia or combinations thereof. Patients previously treated with chemotherapeutic drugs followed by alpha interferon treatment developed even more severe pancytopenia and aplasia. Case reports of two patients who received treatment with alpha interferon 2a are reported here. Both patients were previously treated with chemotherapy, but with a long interval before starting IFN administration. Patient one developed life-threatening bone marrow hypoplasia and aplasia after interferon treatment and died. Patient two showed similar but less severe changes in bone marrow, i.e. thrombocytopenia, mild leukopenia and anemia. The clinical course of both patients was followed by routine peripheral blood tests and bone marrow biopsies and permit some reflection on the pathogenesis of marrow hypoplasia. Myelosuppressive effects of interferon treatment are discussed in the context of chemotherapy effects, cytokine actions and potential additional influences of herpesvirus infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893989

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

1.  Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.

Authors:  Bahram Bodaghi; Gael Gendron; Bertrand Wechsler; Céline Terrada; Nathalie Cassoux; Du Le Thi Huong; Claire Lemaitre; Christine Fradeau; Phuc LeHoang; Jean-Charles Piette
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

Review 2.  [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].

Authors:  N Stübiger; S Winterhalter; U Pleyer; D Doycheva; M Zierhut; C Deuter
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

3.  Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.

Authors:  Sabela Lens; Jose L Calleja; Ana Campillo; Jose A Carrión; Teresa Broquetas; Christie Perello; Juan de la Revilla; Zoe Mariño; María-Carlota Londoño; Jose M Sánchez-Tapias; Álvaro Urbano-Ispizua; Xavier Forns
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

4.  Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report.

Authors:  Savvas Ioannou; Gregorios Hatzis; Ioanna Vlahadami; Michael Voulgarelis
Journal:  J Med Case Rep       Date:  2010-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.